RNA Analysis/ Transcriptomics Market Will Reach $3,773.0 Million by 2019

RNA Analysis is the study of the complete set of RNAs (transcriptome) encoded by the genome of a specific cell or organism at a specific time or under a specific set of conditions. RNA Analysis has significant applications in the field of pharmaceuticals and biotechnology and is used in the drug discovery, life science research, and clinical diagnostic applications. Transcriptomics has its application

Logo

Dallas, TX -- (SBWire) -- 03/09/2015 --The global transcriptomics market is expected to grow at a CAGR of 13.7% during the forecast period of 2014 to 2019 and is estimated to be worth $3,773.0 million by 2019.

The transcriptomics market has blatantly grown in the past few years primarily due to the increasing technological advancements in the field of sequencing technologies in transcriptomics research. Similarly, the increasing government and private funding for research coupled with research and development investments by the biotechnology companies are expected to drive the transcriptomics market. The increasing adoption of transcriptomics in the field of biomarker discovery opens new growth avenues with the rising preference of personalized medicine across the globe. However, the higher investment costs that restrict the adoption of transcriptomics products and dearth of skilled professionals are the factors hampering the growth of this market to a certain extent.

The transcriptomics market report covers the transcriptomic technologies, applications and end-users. The technologies market in this report is segmented as microarray, PCR, sequencing technologies which include Sanger sequencing and NGS, and RNAi gene silencing technology. Each of these technologies market is further sub-segmented into reagents, instruments and software. The applications of transcriptomics covered under the scope of this report are clinical diagnostics, drug discovery, and toxicogenomics. The end-users of transcriptomics are pharmaceutical and biotechnology companies, academic research and government institutes, and hospitals and diagnostic centers. This report also discusses the key market drivers, restraints, opportunities, challenges, and trends in the global transcriptomics market and its submarkets.

Get PDF Brochure:
http://www.marketsandmarkets.com/pdfdownload.asp?id=240344576&utm_source=Sbwire&utm_medium=Referral&utm_campaign=PaidPR

In 2013, North America region holds the majors hare in the global transcriptomics market, followed by Europe and Asia-Pacific. The major share of the North American region is primarily attributed to the presence and expansion of major pharmaceutical and biotechnology companies in this region, especially in the U.S. Similarly, the increasing adoption of transcriptomics in drug discovery and clinical diagnostics has driven the growth of North American transcriptomics market. On the other hand, with the increasing number of biotechnology companies in Asia-Pacific region and thereby the rising research and development activities, the Transcriptomics Market in Asia-Pacific region is expected to grow at the highest rate during the forecast period.

Speak to Analyst:
http://www.marketsandmarkets.com/speaktoanalyst.asp?id=240344576&utm_source=Sbwire&utm_medium=Referral&utm_campaign=PaidPR

The prominent players in the market are Affymetrix Inc. (U.S.), Agilent Technologies Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), GE Healthcare (U.S.), Illumina Inc. (U.S.), Qiagen N.V. (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Sigma Aldrich (U.S.), Fluidigm Corporation (U.S.), and Thermofisher Scientific Inc. (U.S.).

About MarketsandMarkets
MarketsandMarkets is world's No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.

M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Subscribe Reports from Healthcare Domain
http://www.marketsandmarkets.com/Subscription.html?utm_source=Sbwire&utm_medium=Referral&utm_campaign=Subscription-Healthcare

Contact:
Mr. Rohan
North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas, TX 75252
Tel: 888-600-6441
Email: sales@marketsandmarkets.com
Visit MarketsandMarkets Blog
http://www.marketsandmarketsblog.com/market-reports/healthcare/biotechnology
Connect with us on LinkedIn
http://www.linkedin.com/company/marketsandmarkets

Media Relations Contact

Mr. Rohan
888-600-6441
http://www.marketsandmarkets.com/

View this press release online at: http://rwire.com/584812